While BRAF inhibitors (BRAFis), including vemurafenib and dabrafenib, are highly effective in BRAFV600E melanoma (~60–80% response rate)3,4, the response rate of BRAFi monotherapy in BRAFV600E CRC is only 0–5%5,6. Here, BRAF is linked to colorectal carcinoma.